JP2010538049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010538049A5 JP2010538049A5 JP2010523523A JP2010523523A JP2010538049A5 JP 2010538049 A5 JP2010538049 A5 JP 2010538049A5 JP 2010523523 A JP2010523523 A JP 2010523523A JP 2010523523 A JP2010523523 A JP 2010523523A JP 2010538049 A5 JP2010538049 A5 JP 2010538049A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- ethoxy
- glp
- carboxy
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 68
- -1 (1-amino) Cyclohexyl Chemical group 0.000 claims description 27
- 150000001408 amides Chemical group 0.000 claims description 24
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims description 7
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims description 7
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims description 7
- KQMBIBBJWXGSEI-ROLXFIACSA-N (2s)-2-amino-3-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CNC=N1 KQMBIBBJWXGSEI-ROLXFIACSA-N 0.000 claims description 7
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 claims description 7
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims description 7
- UYEGXSNFZXWSDV-BYPYZUCNSA-N (2s)-3-(2-amino-1h-imidazol-5-yl)-2-azaniumylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CNC(N)=N1 UYEGXSNFZXWSDV-BYPYZUCNSA-N 0.000 claims description 7
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims description 7
- IINRZEIPFQHEAP-UHFFFAOYSA-N 1-aminocycloheptane-1-carboxylic acid Chemical compound OC(=O)C1(N)CCCCCC1 IINRZEIPFQHEAP-UHFFFAOYSA-N 0.000 claims description 7
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims description 7
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims description 7
- PJSQECUPWDUIBT-UHFFFAOYSA-N 1-azaniumylcyclooctane-1-carboxylate Chemical compound OC(=O)C1(N)CCCCCCC1 PJSQECUPWDUIBT-UHFFFAOYSA-N 0.000 claims description 7
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 7
- 229930195721 D-histidine Natural products 0.000 claims description 7
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960002885 histidine Drugs 0.000 claims description 7
- OQQDUMSNEFAJOO-MRVPVSSYSA-N (2r)-2-amino-2-(1h-imidazol-5-ylmethyl)-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CC1=CN=CN1 OQQDUMSNEFAJOO-MRVPVSSYSA-N 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 20
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 20
- 150000001413 amino acids Chemical group 0.000 claims 13
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 12
- 229940024606 amino acid Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 0 C*NCCC(C)(C)OCCOCCC1OC1 Chemical compound C*NCCC(C)(C)OCCOCCC1OC1 0.000 description 3
- FZKHGEQUJKGXCB-UHFFFAOYSA-N CC(CCNC)/[O]=C/COCCNC(COCC(N)=O)=O Chemical compound CC(CCNC)/[O]=C/COCCNC(COCC(N)=O)=O FZKHGEQUJKGXCB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07115743 | 2007-09-05 | ||
| EP08101010 | 2008-01-28 | ||
| PCT/EP2008/061833 WO2009030774A1 (en) | 2007-09-05 | 2008-09-05 | Truncated glp-1 derivatives and their therapeutical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010538049A JP2010538049A (ja) | 2010-12-09 |
| JP2010538049A5 true JP2010538049A5 (OSRAM) | 2013-11-21 |
Family
ID=40043001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523523A Withdrawn JP2010538049A (ja) | 2007-09-05 | 2008-09-05 | 切断型ｇｌｐ−１誘導体及びその治療的使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100292133A1 (OSRAM) |
| EP (1) | EP2190873B1 (OSRAM) |
| JP (1) | JP2010538049A (OSRAM) |
| CN (1) | CN101842386A (OSRAM) |
| ES (1) | ES2550363T3 (OSRAM) |
| WO (1) | WO2009030774A1 (OSRAM) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2570133B1 (en) | 2005-11-07 | 2016-03-23 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| WO2008086086A2 (en) | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| WO2009058734A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| WO2009058662A2 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| JP5753779B2 (ja) | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
| JP5775450B2 (ja) | 2008-06-17 | 2015-09-09 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| AR072159A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad |
| WO2010071807A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| BRPI1014508A2 (pt) | 2009-06-16 | 2016-04-05 | Univ Indiana Res & Tech Corp | análogos de peptídeo de glucagon, dimer de dois peptídeos de glucagon, composição farmacêutica deles derivada e métodos para seu uso" |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| BR112012018585A2 (pt) | 2010-01-27 | 2017-01-10 | Univ Indiana Res & Tech Corp | conjungados e composições de glucagon antagonista-gip agonista para o tratamento de distúrbios metabólicos e de obesidade |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| JP6121323B2 (ja) | 2010-05-13 | 2017-05-10 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| KR20130102470A (ko) | 2010-06-24 | 2013-09-17 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그 |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| PL3326620T3 (pl) | 2010-12-16 | 2020-08-24 | Novo Nordisk A/S | Kompozycje stałe zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino)kaprylowego |
| JP6086067B2 (ja) | 2010-12-22 | 2017-03-01 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | Ｇｉｐレセプター活性を示すグルカゴンアナローグ |
| BR112013026195A2 (pt) | 2011-04-12 | 2016-11-29 | Novo Nordisk As | derivados de glp-1 duplamente acilados |
| MX347703B (es) | 2011-06-22 | 2017-05-09 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1. |
| US8729017B2 (en) | 2011-06-22 | 2014-05-20 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| CN104039822A (zh) | 2011-09-06 | 2014-09-10 | 诺沃—诺迪斯克有限公司 | Glp-1衍生物 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| KR20140097151A (ko) | 2011-11-17 | 2014-08-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| HUE062740T2 (hu) | 2012-03-22 | 2023-12-28 | Novo Nordisk As | GLP-1 peptidek készítményei és elõállításuk |
| DK2827845T3 (en) | 2012-03-22 | 2019-04-01 | Novo Nordisk As | COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF |
| CN111494323B (zh) | 2012-03-22 | 2023-03-28 | 诺和诺德股份有限公司 | 包含递送剂的组合物及其制备 |
| US9993430B2 (en) | 2012-06-20 | 2018-06-12 | Novo Nordisk A/S | Tablet formulation comprising semaglutide and a delivery agent |
| US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| DK2866825T3 (da) | 2012-07-01 | 2020-06-08 | Novo Nordisk As | Anvendelse af langstidsvirkende glp-1-peptider |
| WO2014060472A1 (en) | 2012-10-17 | 2014-04-24 | Novo Nordisk A/S | Fatty acid acylated amino acids for oral peptide delivery |
| US20150297573A1 (en) | 2012-10-24 | 2015-10-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL |
| PT2991671T (pt) | 2013-05-02 | 2018-11-05 | Novo Nordisk As | Dosagem oral de compostos de glp-1 |
| ES2630106T3 (es) | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| AU2016335287A1 (en) | 2015-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| MA50358A (fr) | 2017-10-12 | 2020-08-19 | Novo Nordisk As | Sémaglutide en thérapie médicale |
| SG11202006595RA (en) | 2018-02-02 | 2020-08-28 | Novo Nordisk As | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| EP3773475A1 (en) | 2018-04-06 | 2021-02-17 | Cyprumed GmbH | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CN110845601B (zh) * | 2019-10-12 | 2021-01-19 | 广东药科大学 | 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用 |
| US20240239862A1 (en) * | 2019-12-30 | 2024-07-18 | Gan & Lee Pharmaceuticals Co., Ltd. | Insulin Derivative |
| KR20220119731A (ko) * | 2019-12-30 | 2022-08-30 | 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 | 장기 지속형 glp-1 화합물 |
| CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
| US20230165939A1 (en) | 2020-04-29 | 2023-06-01 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
| CN116419750A (zh) | 2020-09-07 | 2023-07-11 | 西普鲁梅有限公司 | 改进的glp-1受体激动剂的药物制剂 |
| KR20230083294A (ko) | 2020-09-30 | 2023-06-09 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 폴리펩타이드 접합체 및 사용 방법 |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| CN115960202B (zh) * | 2021-10-09 | 2023-07-14 | 合肥天汇生物科技有限公司 | 一种glp-1类似物及其制备方法和应用 |
| CN115850438B (zh) * | 2021-12-28 | 2023-05-12 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| CA3252113A1 (en) | 2022-03-30 | 2023-10-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Liquid pharmaceutical compositions of polypeptide conjugates and their methods of use |
| JP2025538527A (ja) * | 2022-11-21 | 2025-11-28 | イーライ リリー アンド カンパニー | Ｇｉｐ／ｇｌｐ１デュアルアゴニストを調製するためのプロセス |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2073856C (en) * | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5968899A (en) * | 1994-06-03 | 1999-10-19 | Tsumura & Co. | Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| JP3149958B2 (ja) * | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ―１誘導体 |
| US7235627B2 (en) * | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| WO1998020895A1 (en) * | 1996-11-12 | 1998-05-22 | Novo Nordisk A/S | Use of glp-1 peptides |
| JP2003522099A (ja) | 1998-02-27 | 2003-07-22 | ノボ ノルディスク アクティーゼルスカブ | 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン |
| WO2000034331A2 (en) | 1998-12-07 | 2000-06-15 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Analogues of glp-1 |
| DK1180121T3 (da) | 1999-05-17 | 2004-03-01 | Conjuchem Inc | Langtidsvirkende insulinotrope peptider |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| WO2002046227A2 (en) * | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
| EP2022505B1 (en) * | 2001-07-31 | 2011-12-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
| EA009366B1 (ru) | 2003-03-19 | 2007-12-28 | Эли Лилли Энд Компани | Связанные с полиэтиленгликолем соединения гпп-1 |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| AU2004298424A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel GLP-1 compounds |
| EP2289560B1 (en) * | 2004-07-08 | 2015-04-22 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
| US7893017B2 (en) * | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
| WO2006097535A2 (en) * | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Peptide agonists of the glucagon family with secretin like activity |
| TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| WO2006097536A2 (en) * | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| WO2006097538A1 (en) * | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Extended glp-1 compounds |
| EP2190872B1 (en) * | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
-
2008
- 2008-09-05 EP EP08803802.1A patent/EP2190873B1/en not_active Not-in-force
- 2008-09-05 CN CN200880114458A patent/CN101842386A/zh active Pending
- 2008-09-05 WO PCT/EP2008/061833 patent/WO2009030774A1/en not_active Ceased
- 2008-09-05 ES ES08803802.1T patent/ES2550363T3/es active Active
- 2008-09-05 US US12/676,453 patent/US20100292133A1/en not_active Abandoned
- 2008-09-05 JP JP2010523523A patent/JP2010538049A/ja not_active Withdrawn
-
2014
- 2014-06-09 US US14/299,638 patent/US9657079B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010538049A5 (OSRAM) | ||
| JP2008533105A5 (OSRAM) | ||
| RU2007134156A (ru) | Ацилированные glp-1 соединения | |
| RU2007134155A (ru) | Glp-1 соединения с увеличенным временем полужизни | |
| JP2014529629A5 (OSRAM) | ||
| JP2014501712A5 (OSRAM) | ||
| US20150133373A1 (en) | Transmucosal delivery of engineered polypeptides | |
| US9382304B2 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| CN103370083B (zh) | 具有增强的作用持续时间的工程化多肽 | |
| JP2005528337A5 (OSRAM) | ||
| JP2008507477A5 (OSRAM) | ||
| JP2011520847A5 (OSRAM) | ||
| RU2006120079A (ru) | Производные глюкагоноподобного пептида-1 (glp-1) | |
| JP2023510218A (ja) | 長時間作用型ｇｌｐ－１化合物 | |
| JP2016526012A5 (OSRAM) | ||
| US20090062192A1 (en) | Dimeric Peptide Agonists of the Glp-1 Receptor | |
| RU2006144821A (ru) | Пролонгирующие метки полипептидов, содержащие тетразольную группировку | |
| JP2012506402A5 (OSRAM) | ||
| JP2011520847A (ja) | 遅効型ｙ２及び／又はｙ４レセプターアゴニスト | |
| TW201010729A (en) | GIP-based mixed agonists for treatment of metabolic disorders and obesity | |
| JP2007537142A (ja) | アルブミン様物質に結合した新規のｇｌｐ−１類似物 | |
| JP2018504111A (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| JP2015517477A5 (OSRAM) | ||
| CN111132690A (zh) | 胰高血糖素和glp-1受体的长效共激动剂 | |
| WO2008145721A2 (en) | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |